PPARG and prostate carcinoma: PPARγ activation has been implicated to inhibit the proliferation of malignant cells from different lineages such as liposarcoma [24], breast adenocarcinoma [12], prostate carcinoma [25], colorectal carcinoma [26], non-small-cell lung carcinoma [27], pancreatic carcinoma [28], bladder cancer cells [29], and gastric carcinoma cells [30].